Progenics Pharmaceuticals Articles
AstraZeneca's Brilinta gains Class I in ACCF/AHA Guidelines; enters deal with Progenics
18 December 2012
CytoDyn to acquire Progenics' PRO 140
31 July 2012
Progenics Pharma grants rights to Salix for Relistor, in upfront $60 million and potential $290 million more deal
8 February 2011
Showing 1-4 of 4 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
